Annexon (NASDAQ:ANNX) Upgraded at Zacks Research

Zacks Research upgraded shares of Annexon (NASDAQ:ANNX) from a strong sell rating to a hold rating in a report issued on Monday,Zacks.com reports.

Other equities research analysts also recently issued research reports about the stock. Needham & Company LLC cut their target price on shares of Annexon from $16.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, May 13th. HC Wainwright reiterated a “buy” rating and issued a $14.00 target price on shares of Annexon in a research report on Friday, August 15th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $12.50.

Annexon Stock Performance

Shares of NASDAQ:ANNX opened at $2.14 on Monday. The company has a market cap of $235.16 million, a PE ratio of -1.66 and a beta of 1.30. Annexon has a 52 week low of $1.28 and a 52 week high of $7.85. The firm has a 50 day simple moving average of $2.48 and a 200 day simple moving average of $2.34.

Annexon (NASDAQ:ANNX) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.02. On average, equities analysts predict that Annexon will post -0.96 earnings per share for the current year.

Institutional Trading of Annexon

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Matauro LLC bought a new position in shares of Annexon during the 2nd quarter worth about $27,000. BNP Paribas Financial Markets bought a new position in Annexon during the 4th quarter valued at about $59,000. 49 Wealth Management LLC bought a new position in Annexon during the 2nd quarter valued at about $29,000. Vanguard Personalized Indexing Management LLC bought a new position in Annexon during the 2nd quarter valued at about $29,000. Finally, Engineers Gate Manager LP bought a new position in Annexon during the 2nd quarter valued at about $32,000.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.